Exososmes in Atrophic Scars Management
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Intralesional exosomes, Intralesional Saline.
- Who it may be relevant to
- Registry conditions: Atrophic Scar. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Intralesional Exosomes Versus Intralesional Saline in The Treatment of Atrophic Scars: A Randomized Controlled Trial
Overview
Lay Summary (Simple Explanation) Atrophic scars are depressed scars that form when the skin does not heal properly, commonly seen after acne or injuries. These scars can affect appearance and confidence, and current treatments may not always give satisfactory results. This study aims to evaluate a new treatment using exosomes, which are tiny particles naturally released by cells that help in skin repair and regeneration. Researchers will compare the effect of injecting exosomes directly into scars versus injecting a simple saltwater solution (saline), which serves as a control. Participants will be randomly assigned to receive either exosome injections or saline injections. Neither the patient nor the evaluator may know which treatment is given, to ensure fair comparison. The goal is to determine whether exosomes can safely and effectively improve the appearance and texture of atrophic scars.
Interventions
- Other Intralesional exosomes
exosomes are injected within the substance of the scar. - Other Intralesional Saline
all patients will receive both, exosomes and saline, each injected into one scar.
Primary outcome measures
- modified Manchester Scar Scale [Time frame: 3 months after 4 biweekly sessions]
Secondary outcome measures (1)
- Scar thickness measurement in millimetres by Ultrasound examination [Time frame: 3 months after 4 biweekly sessions]
Eligibility criteria
Inclusion criteria
Age >18 years
- Either gender
- Scars of any duration
- Multiple scars at one side or both sides of the face.
- Patients are willing to sign written informed consent statements before beginning treatment.
Exclusion criteria
- Pregnant females.
- Patients with one scar.
- Hypersensitivity to any of the used treatments.
- Patient with infection at the site of the scar.
- Patients with unrealistic expectations.
- Patient refusing to sign on the consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Zagazig University Hospitals — Zagazig
Identifiers
NCT: NCT07569666 · 1125/2-3-2025